JP5777200B2 - 抗デングウイルス剤 - Google Patents
抗デングウイルス剤 Download PDFInfo
- Publication number
- JP5777200B2 JP5777200B2 JP2010248271A JP2010248271A JP5777200B2 JP 5777200 B2 JP5777200 B2 JP 5777200B2 JP 2010248271 A JP2010248271 A JP 2010248271A JP 2010248271 A JP2010248271 A JP 2010248271A JP 5777200 B2 JP5777200 B2 JP 5777200B2
- Authority
- JP
- Japan
- Prior art keywords
- dengue virus
- well
- cells
- methyl
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012310 Dengue fever Diseases 0.000 title description 33
- 208000025729 dengue disease Diseases 0.000 title description 27
- 241000700605 Viruses Species 0.000 title description 25
- 208000001490 Dengue Diseases 0.000 title description 16
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 34
- 150000001875 compounds Chemical class 0.000 description 30
- -1 small molecule compounds Chemical class 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 14
- 208000009714 Severe Dengue Diseases 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 9
- 241000725619 Dengue virus Species 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 201000009892 dengue shock syndrome Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- HOVAGTYPODGVJG-VOQCIKJUSA-N methyl beta-D-galactoside Chemical compound CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-VOQCIKJUSA-N 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- VVSWDMJYIDBTMV-UQPQVDFHSA-N (2r,4ar,6s,7r,8r,8as)-6-methoxy-2-phenyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxine-7,8-diol Chemical compound C1([C@@H]2OC[C@H]3O[C@@H]([C@@H]([C@@H](O)[C@@H]3O2)O)OC)=CC=CC=C1 VVSWDMJYIDBTMV-UQPQVDFHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- LNRUAGKMPCNDEX-OVHBTUCOSA-N [(2R,3R,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl] hydrogen sulfate Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]1O LNRUAGKMPCNDEX-OVHBTUCOSA-N 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- ZNCXUFVDFVBRDO-UHFFFAOYSA-N pyridine;sulfuric acid Chemical class [H+].[O-]S([O-])(=O)=O.C1=CC=[NH+]C=C1 ZNCXUFVDFVBRDO-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DTHWTSKHYKXVRC-KJZJDBPNSA-N (2S,3S,4S,5R,6S)-3,4,5,6-tetrahydroxy-6-methyloxane-2-carboxylic acid Chemical compound C[C@@]1(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)C(=O)O DTHWTSKHYKXVRC-KJZJDBPNSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000710815 Dengue virus 2 Species 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000008710 crystal-8 Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940023605 dengue virus vaccine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000018320 severe joint pain Diseases 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical class O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
のいずれかで表される化合物またはその薬学的に許容しうる塩,ならびにこれらの化合物またはその薬学的に許容しうる塩を有効成分として含む抗デングウイルス剤を提供する。R1は、好ましくはメチルまたはオクチルであり、特に好ましくはメチルである。これらの中でも、メチルα−GlcA(3−O−S)、メチルβ−Gal(3−O−S)、およびメチルβ−Gal(3,6−O−S)が好ましく、メチルα−GlcA(3−O−S)が更に好ましい(略号については下記の表を参照)。
ダルベッコ改変イーグル培地(DMEM:Dulbecco's Modified Eagle medium) (05919, ニッスイ)
デングウイルス2型(D2/ThNH7:1997年にタイ国のdengue shock syndrome (DSS) 患者より単離されたウイルス)
1次抗体:3H5-1 (ATCC, HB-46)
1次抗体:DHF (デング出血熱患者)血清
2次抗体:ヤギ抗マウスIgG (115-035-068, Jackson )
2次抗体:ヤギ抗ヒトIgG (109-036-127, Jackson )
Igepal-CA630 (13021-100ML, SIGMA)
ウシ血清アルブミン(BSA) (10 735 094 001, Roche)
パラホルムアルデヒド(162-16065, 和光純薬工業株式会社)
トラガカントゴム(206-0224, 和光純薬工業株式会社)
KONIKA イムノステインHRP-1000 (130990, 生化学工業)
実験に用いた低分子糖誘導体の名称と構造,ならびに図面で用いられている略称を下記の表に示す。
メチル α-グルクロン酸 (3-O-SO3H)は,下記のスキームにより合成した。
アルゴン雰囲気下,化合物 4(10.0 g, 51.0 mmol)をベンズアルデヒド(25 ml)に溶かし,ZnCl2(7.0 g, 51.3 mmol)を加え,室温で12時間撹拌した。反応液に氷水を加え,析出した結晶を吸引ろ取し乾燥した。この結晶をシリカゲルクロマトグラフィー(展開溶媒:酢酸エチル:ヘキサン=1:1)で精製して無色結晶体 5 (9.93 g, 69%)を得た。
1H-NMR(CDCl3)δ:3.46 (3H, s, -OCH3), 3.50 (1H, t, J = 9.5 Hz, H-4), 3.63 (1H, dd, J = 9.5 Hz, 4.0 Hz, H-2), 3.74 (1H, t, J = 9.5 Hz, H-6a), 3.81 (1H, m, H-5), 3.92 (1H, t, J = 9.5 Hz, H-3), 4.29 (1H, m, H-6b), 4.80 (1H, d, J = 4.0 Hz, H-1), 5.53 (1H, s, -CHPh), 7.25-7.48 (5H, m, -C6H5)
アルゴン雰囲気下,化合物 5(609 mg, 2.16 mmol)をピリジン(8 ml)に溶かし,無水酢酸(384 mg, 3.52 mmol)を加え,0 ℃で3時間撹拌した。反応液を減圧下濃縮し,残渣をシリカゲルクロマトグラフィー(展開溶媒:酢酸エチル:ヘキサン=1:1)で精製して無色結晶体 8(140 mg, 20%)を得た。
1H-NMR(CDCl3)δ:3.40 (3H, s, -OCH3), 3.56 (1H, t, J = 10 Hz, H-4), 3.76 (1H, t, J = 10 Hz, H-6a), 3.84 (1H, m, H-6a), 4.17 (1H, t, J = 10 Hz, H-3), 4.29 (1H, m, H-6b), 4.80 (1H, dd, J = 10, 3.5 Hz, H-2), 4.95 (1H, d, J = 3.5 Hz, H-1), 5.55 (1H, s, -CHPh), 7.35-7.50 (5H, m, -C6H5)
窒素雰囲気下,化合物 8(270 mg, 0.83 mmol)をピリジン(6 ml)に溶かし,硫酸ピリジン複合体(198 mg, 1.25 mmol)を加え,50 ℃で11時間撹拌した。反応液を減圧下濃縮し,残渣をシリカゲルクロマトグラフィー(展開溶媒:クロロホルム:メタノール:水=65:35:5)で精製して無色油状物9(75.5 mg, 22%)を得た。
1H-NMR(D2O)δ:3.32 (3H, s, -OCH3), 3.73-3.82 (3H, m, H-4, H-6a, H-5), 4.18 (1H, m, H-6b), 4.33 (1H, dd, J = 10 Hz, 4.0 Hz, H-2), 4.98 (1H, d, J = 4.0 Hz, H-1), 5.22 (1H, t, J = 10 Hz, H-3), 5.45 (1H, s, -CHPh), 7.30-7.40 (5H, m, -C6H5). FAB-MS:m/z 403 (M-H)-
化合物 9(66 mg, 0.16 mmol)を水(3 ml)に溶かし,アンバーライトIR120(H+)を少量加えpH 2-3に調整して,60 ℃で1時間撹拌した。反応液を吸引ろ過し,ろ液を減圧下濃縮し,残渣をシリカゲルクロマトグラフィー(展開溶媒:クロロホルム:メタノール:水=65:35:5)で精製して無色結晶体 10(39.2 mg, 89%)を得た。FAB-MS:m/z 273 (M-H)-
化合物 10(39.2 mg, 0.14 mmol)をアセトニトリル緩衝液(pH 6.9)(1:1)(2 ml)に溶かし,NaClO2(63 mg, 0.70 mmol)と12% w/w NaClO水溶液(50 μl)を順次加え,TEMPO(10.9 mg, 0.07 mmol)を加え,室温で5時間撹拌した。粗生成物をゲル濾過クロマトグラフィーに賦して精製後,凍結乾燥して無色結晶体 2(35 mg, 83%)を得た。FAB-MS:m/z 287 (M-H)-
3-1. 細胞培養
デングウイルス感染実験には,ハムスター腎由来細胞であるBHK-21細胞を用いた。BHK-21細胞を5% FBS及び1%PSG含有DMEM (ニッスイ, 05919) 培地中で37℃,5 %CO2存在下で培養した。
BHK21細胞を感染実験前日に96 ウエルプレート(167008, nunc)に2.5 x 104 細胞/0.1ml/ウエルとなるように播きこんだ。5% ウシ胎児血清(FBS)-DMEM培地で,37℃,5% CO2存在下,細胞がコンフルエントになるまで培養し,以後の感染実験に用いた。
細胞表面ウイルス結合アッセイにはBHK-21細胞を用いた。BHK-21細胞の培養法については前述の通りである。ウイルスと培養細胞との直接的な結合を細胞表面ウイルス結合アッセイにより評価した。
Claims (1)
- 次式:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010248271A JP5777200B2 (ja) | 2010-11-05 | 2010-11-05 | 抗デングウイルス剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010248271A JP5777200B2 (ja) | 2010-11-05 | 2010-11-05 | 抗デングウイルス剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012097054A JP2012097054A (ja) | 2012-05-24 |
JP5777200B2 true JP5777200B2 (ja) | 2015-09-09 |
Family
ID=46389395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010248271A Active JP5777200B2 (ja) | 2010-11-05 | 2010-11-05 | 抗デングウイルス剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5777200B2 (ja) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005015451A (ja) * | 2003-06-30 | 2005-01-20 | Japan Science & Technology Agency | 硫酸化グルコース化合物 |
EP1699806A1 (en) * | 2003-12-23 | 2006-09-13 | Progen Industries Limited | Glycosaminoglycan (gag) mimetics |
-
2010
- 2010-11-05 JP JP2010248271A patent/JP5777200B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2012097054A (ja) | 2012-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2718690C2 (ru) | Способы и композиции для ингибирования полимеразы | |
US20230248754A1 (en) | Patentiflorin A Analogs as Antiviral Agents | |
TW201623265A (zh) | 抗病毒化合物、醫藥組合物及其使用方法 | |
Karagozlu et al. | Anti-HIV activities of novel synthetic peptide conjugated chitosan oligomers | |
Oka et al. | Syntheses and biological evaluations of carbosilane dendrimers uniformly functionalized with sialyl α (2→ 3) lactose moieties as inhibitors for human influenza viruses | |
US9284292B2 (en) | Sialochimeric compounds | |
JP5777200B2 (ja) | 抗デングウイルス剤 | |
CN109771432B (zh) | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 | |
KR101097189B1 (ko) | 디히드록시크로몬 유도체를 유효성분으로 함유하는 코로나바이러스로 인해 유발되는 질환의 치료 및 예방을 위한 약학 조성물 | |
WO2023048151A1 (ja) | ウイルス増殖阻害活性を有する環状ペプチド | |
US6664235B1 (en) | Medicaments comprising sialic acid derivatives as active ingredients | |
JP2001131074A (ja) | シアル酸誘導体を有効成分として含む医薬 | |
WO2011013398A1 (ja) | Cd22分子に対する高親和性を有しb細胞の増殖を増強する化合物 | |
KR101045985B1 (ko) | 아릴 디케토산(adk) 유도체를 유효성분으로 포함하는 사스 코로나 바이러스 저해용 조성물 | |
RU2697716C1 (ru) | Гидрохлорид 1,7,7-триметилбицикло[2.2.1]гептан-2-ил 3-(пиперидин-1-ил)пропионат, используемый в качестве ингибитора вируса Эбола | |
US20240076299A1 (en) | Tuberculatin analogs as antiviral agents | |
WO2022138696A1 (ja) | コロナウイルス感染症を予防又は治療するための医薬組成物 | |
JP2006241024A (ja) | 新規シアル酸誘導体 | |
EP3050871A1 (en) | Novel bis-amide derivative and use thereof | |
JPWO2004076471A1 (ja) | ビフラボノイドシアル酸配糖体からなる抗インフルエンザウイルス化合物 | |
JP2003246792A (ja) | 抗インフルエンザウイルス化合物 | |
WO2003049672A2 (en) | Methods and compositions for treating flavivirus-mediated disease | |
WO1999043689A1 (fr) | Nouveaux derives de kdn et medicaments les contenant sous forme de principes actifs | |
JPH10158225A (ja) | ウイルス産生阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20131017 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131017 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150623 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150703 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5777200 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |